CROSSJECT (EPA:ALCJ) | WebDisclosure

Basculer en Français

10400	Companies
217250	Keywords
146886	Articles
115004	Press releases

Home
Companies
CROSSJECT

PRESS RELEASE

published on 06/24/2025 at 19:00, 10 months 18 days ago

CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 millions d’euros après exercice intégral de la clause d’extension
CROSSJECT annonce le vif succès de son augmentation de capital à 5,7 millions d’euros après exercice intégral de la clause d’extension pour ZEPIZURE®

Financement Augmentation De Capital Pharmaceutique Crossject ZEPIZURE
PRESS RELEASE

published on 06/24/2025 at 19:00, 10 months 18 days ago

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause
CROSSJECT successfully completes a capital increase of €5.7 million through preferential subscription rights, benefiting from new investor support and Gemmes Venture, to advance ZEPIZURE® development

Capital Increase Crossject ZEPIZURE® Gemmes Venture Vatel Capital
BRIEF

published on 06/11/2025 at 07:35, 11 months 2 days ago

CROSSJECT advances in the development of ZEPIZURE® Junior for children

Epilepsy Pediatrics Crossject Auto-injector ZEPIZURE Junior
BRIEF

published on 06/11/2025 at 07:35, 11 months 2 days ago

CROSSJECT progresse dans le développement de ZEPIZURE® Junior pour enfants

Pédiatrie Crossject Auto-injecteur Épilepsie ZEPIZURE Junior
PRESS RELEASE

published on 06/11/2025 at 07:30, 11 months 2 days ago

CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
CROSSJECT advances development of ZEPIZURE® Junior for epilepsy crises in children, completing clinical studies for effective calibration and injection depth validation

Epilepsy Clinical Studies Crossject ZEPIZURE® Junior Pediatric Population
PRESS RELEASE

published on 06/11/2025 at 07:30, 11 months 2 days ago

CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les crises d'épilepsie chez l'enfant
CROSSJECT progresse dans le développement de ZEPIZURE® Junior pour les crises d'épilepsie chez l'enfant, avec calibration réussie de ZENEO®. Étude clinique menée pour adapter l'injection aux enfants

Crossject Enfant ZENEO® Épilepsie ZEPIZURE® Junior
BRIEF

published on 06/06/2025 at 17:50, 11 months 6 days ago

Publication des droits de vote et actions de Crossject

Droits De Vote Capital Social Actions AMF Crossject
BRIEF

published on 06/06/2025 at 17:50, 11 months 6 days ago

Publication of Crossject voting rights and shares

Share Capital Voting Rights Actions AMF Crossject
PRESS RELEASE

published on 06/06/2025 at 17:45, 11 months 6 days ago

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
CROSSJECT publie le nombre total de droits de vote et d'actions au 31 mai 2025, incluant les informations sur son capital social et ses activités pharmaceutiques

Droits De Vote Capital Social Pharmaceutique Crossject Urgence
BRIEF

published on 06/04/2025 at 20:26, 11 months 8 days ago

CROSSJECT lance une augmentation de capital de près de 5 millions d'euros

Investissement Augmentation De Capital Pharmaceutique Droit Préférentiel De Souscription ZEPIZURE®

Accesswire

Published on 05/13/2026 at 15:30, 2 hours 10 minutes ago

All Things Mobile Analytic, Inc. (OTCID:ATMH) Acquires Metis Technology S.p.A., Strengthening European Enterprise Capabilities
Published on 05/13/2026 at 15:05, 2 hours 35 minutes ago

Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
Published on 05/13/2026 at 15:00, 2 hours 40 minutes ago

ACCESS Newswire to Present at the LD Micro Invitational XVI on May 19th, at 2:00 pm ET
Published on 05/13/2026 at 15:00, 2 hours 40 minutes ago

Caldwell Announces Relaunch of Canada's Top 40 Under 40(R) Award Program
Published on 05/13/2026 at 14:35, 3 hours 5 minutes ago

INEO Announces Patented INEO Welcoming DUO in Full Production with First Installation Underway in Leading UK Retailer

View all ACCESSWIRE

EQS Group

Published on 05/13/2026 at 17:20, 19 minutes ago

Uzin Utz SE: Annual General Meeting approves dividend for the 2025 fiscal year
Published on 05/13/2026 at 16:50, 50 minutes ago

Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
Published on 05/13/2026 at 16:05, 1 hour 35 minutes ago

PR Emerges as the Primary Source for Journalists in High-Pressure Newsrooms
Published on 05/13/2026 at 16:05, 1 hour 35 minutes ago

Coupa and Celonis Collaborate to Eliminate Value Leakage Across Autonomous Spend Management
Published on 05/13/2026 at 15:57, 1 hour 43 minutes ago

MLP SE: Invitation to the Annual General Meeting of MLP SE published

Les Echos

Published on 05/13/2026 at 16:00, 1 hour 40 minutes ago

MONTHLY INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES
Published on 05/13/2026 at 16:00, 1 hour 40 minutes ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL
Published on 05/13/2026 at 14:31, 3 hours 8 minutes ago

Statement of transactions in own shares from May 4, 2026 to May 8, 2026
Published on 05/13/2026 at 14:31, 3 hours 8 minutes ago

Déclaration des transactions sur actions propres réalisées du 04/05/2026 au 08/05/2026
Published on 05/13/2026 at 12:27, 5 hours 12 minutes ago

Franchisee Litigation - The Paris Court of Appeal Rules in Favor of Carrefour

View all LES ECHOS COMFI WIRE